Purple Biotech Ltd
PPBT
$2.30
$0.0251.10%
NASDAQ
| 06/30/2025 | 12/31/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -68.37% | -- | -- | |
| Gross Profit | -- | 68.37% | -- | -- | |
| SG&A Expenses | -21.04% | -40.17% | -39.51% | -35.78% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -62.04% | -83.79% | -36.59% | -12.81% | |
| Operating Income | 62.04% | 83.79% | 36.59% | 12.81% | |
| Income Before Tax | 54.91% | 91.46% | 53.20% | 22.88% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | 54.91% | 91.46% | 53.20% | 22.88% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -60.00% | -83.87% | -54.55% | -24.00% | |
| Net Income | 54.89% | 91.51% | 53.19% | 22.88% | |
| EBIT | 62.04% | 83.79% | 36.59% | 12.81% | |
| EBITDA | 62.92% | 83.89% | 36.89% | 12.96% | |
| EPS Basic | 77.01% | 94.65% | 64.49% | 43.50% | |
| Normalized Basic EPS | 76.00% | 94.87% | 67.11% | -- | |
| EPS Diluted | 77.01% | 94.71% | 64.49% | 43.50% | |
| Normalized Diluted EPS | 76.00% | 94.87% | 67.11% | -- | |
| Average Basic Shares Outstanding | 98.77% | 59.08% | 31.07% | 36.67% | |
| Average Diluted Shares Outstanding | 98.77% | 59.08% | 31.07% | 36.67% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |